E. Imoukhuede

发表

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial

James D. Campbell, M. Levine, R. Koup, 2016, The Lancet. Infectious diseases.

A multimedia consent tool for research participants in the Gambia: a randomized controlled trial

N. McGrath, K. Bojang, H. Larson, 2015, Bulletin of the World Health Organization.

Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.

K. Bojang, T. Lang, B. Greenwood, 2006, Vaccine.

Multimedia Informed Consent Tool for a Low Literacy African Research Population: Development and Pilot-Testing

N. McGrath, K. Bojang, H. Larson, 2014, Journal of clinical research & bioethics.

Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA.

K. Marsh, C. Loucq, R. Sauerwein, 2009, Vaccine.

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

D. Webster, A. Hill, G. Walraven, 2004, The Journal of infectious diseases.

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal

A. Lawrie, A. Hill, S. Mboup, 2018, The Journal of infectious diseases.

European malaria vaccine initiative: Portfolio and perspectives for the future

O. Leroy, E. Imoukhuede, Roland Ventura, 2010, Human vaccines.

Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02

A. Thomas, Joe D. Cohen, O. Ofori-Anyinam, 2008, PloS one.

A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian Adults

K. Bojang, P. Kaye, B. Greenwood, 2004, PLoS medicine.

Early phase clinical trials with human immunodeficiency virus-1 and malaria vectored vaccines in The Gambia: frontline challenges in study design and implementation.

K. Bojang, B. Kampmann, E. Imoukhuede, 2014, The American journal of tropical medicine and hygiene.

Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum.

K. Bojang, A. Hill, P. Milligan, 2011, The Journal of infectious diseases.

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

P. Bejon, S. Sirima, A. Lawrie, 2018, PloS one.

Safety and Immunogenicity of ChAd 63 and MVA ME-TRAP in West African Children and Infants

R. Cortese, A. Nicosia, K. Bojang, 2022 .

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults

A. Nicosia, K. Marsh, P. Njuguna, 2015, Science Translational Medicine.

Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial

B. Cissé, B. Faye, R. Cortese, 2017, Frontiers in Immunology.

Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants

R. Cortese, K. Bojang, S. Sirima, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal

B. Cissé, J. Gomis, O. Gaye, 2016, PloS one.

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants

R. Cortese, A. Nicosia, K. Bojang, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.

R. Cortese, A. Nicosia, K. Bojang, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults

R. Cortese, A. Nicosia, K. Bojang, 2013, PloS one.

Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate.

B. Mordmüller, P. Kremsner, J. Knobloch, 2009, Vaccine.

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.

Edward Wright, Thomas Strecker, Paul Chaplin, 2015, The New England journal of medicine.

A Randomized Controlled Phase Ib Trial of the Malaria Vaccine Candidate GMZ2 in African Children

R. Noor, B. Mordmüller, S. Issifou, 2011, PloS one.

European Vaccine Initiative: lessons from developing malaria vaccines

A. Craig, O. Leroy, E. Imoukhuede, 2011, Expert review of vaccines.

Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon.

R. Noor, W. Kilama, B. Mordmüller, 2010, Vaccine.

Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area.

K. Bojang, C. Buckee, T. Lang, 2007, The American journal of tropical medicine and hygiene.

PIPS one Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA 1 Malaria Vaccine Adjuvanted with Alhydrogel TM , Montanide ISA 720 or AS 02

A. Thomas, Joe D. Cohen, O. Ofori-Anyinam, 2017 .

Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors

S. Sirima, A. Hill, E. Imoukhuede, 2014, Clinical and Vaccine Immunology.

Digitised audio questionnaire for assessment of informed consent comprehension in a low-literacy African research population: development and psychometric evaluation

N. McGrath, K. Bojang, H. Larson, 2014, BMJ Open.

Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers

S. Sirima, B. Angus, A. Lawrie, 2019 .

Health Providers’ Perceptions of Clinical Trials: Lessons from Ghana, Kenya and Burkina Faso

S. Owusu-Agyei, D. Chandramohan, S. Sirima, 2015, PloS one.

Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara

R. Noor, O. Toure, O. Doumbo, 2016, Malaria Journal.

Template protocol for clinical trials investigating vaccines--focus on safety elements.

Robert T. Chen, S. Kochhar, D. Nalin, 2013, Vaccine.

O. Toure, O. Doumbo, A. Thomas, 2016, Malaria Journal.

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.

R. Cortese, A. Nicosia, K. Bojang, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.